



The Richard Doll Seminars
in Public Health & Epidemiology

**Prof Sir Rory Collins &
Dr Naomi Allen**

*Clinical Trial Service Unit and Epidemiological
Studies Unit, University of Oxford*

**“The UK Biobank study: an
overview and update”**

Tuesday 26th Feb 2013
1-2 pm

Lecture Theatre, Richard Doll Bldg, Old Road Campus

<http://www.ceu.ox.ac.uk/seminars>

Follow us  [@rdseminars](https://twitter.com/rdseminars)

All welcome



Prof Sir Rory Collins & Dr Naomi Allen
CTSU, University of Oxford

After training in medicine and statistics **Professor Sir Rory Collins** became co-director of the University of Oxford’s CTSU in 1985. In 1996 he was appointed Professor of Medicine and Epidemiology at Oxford, supported by the British Heart Foundation. Since September 2005, he has also been acting as the Principal Investigator and Chief Executive of the UK Biobank prospective study of 0.5 million British men and women aged 40-69 years.



His work has been in the establishment of large-scale epidemiological studies of the causes, prevention and treatment of heart attacks, other vascular disease, and cancer, while also being closely involved in developing approaches to the combination of results from related studies in “meta-analyses”. In 2011 he was knighted for his services to science.



Dr Naomi Allen obtained her DPhil in cancer epidemiology from the University of Oxford in 2000. Following this she continued work in the Cancer Epidemiology Unit where she worked on the EPIC-Oxford study and the Million Women Study. In 2011 she joined CTSU as a Senior Research Fellow and Senior Epidemiologist for the UK Biobank.

Her research interests focus on the role of hormones, insulin-like growth factors and nutritional biomarkers in cancer development, particularly cancers of the prostate but also of the breast, ovary and endometrium. She is particularly interested in the association between blood levels of hormones on cancer risk and their genetic and environmental determinants. She is Principal Investigator of the Endogenous Hormones and Prostate Cancer Collaborative Group.